doi.org/10.1186/s128...
Excellent paper led by Dr Charlotte Snead - we need to find ways of consulting with people about kidney disease that support them to make person-centred decisions.
@lucyselman.bsky.social @rachaelmorton.bsky.social @flissmurtagh.bsky.social @peolcsw.bsky.social
Visual abstract of the study from Corina
We need a good biomarker for IgAN given the impoartance of immunosuppression (vs non-specific therapies: RASi, Flozins, ERA)
But the Gd-IgA doesn’t seem so impressive to me?
journals.lww.com/cjasn/pages/...
#NephSky @asnpublications.bsky.social #CJASN
VA by @corinateodosiu.bsky.social
Visual abstract
How common is kidney failure with MCD and FSGS?
More than we think … @brianrifkin.bsky.social breaks down the recent @asnpublications.bsky.social JASN paper from the RaDaR study www.nephjc.com/news/nephjc-...
🚨 Exciting Fellowships! 🚨
Join UHB NHS FT as a Clinical Research Fellow in Renal Medicine (12m fixed term, £65k, Birmingham).
Apply now:
🧠 Dialysis & Cognition: jobs.nhs.uk/candidate/joba…
💉 Hypertension & Dialysis: jobs.nhs.uk/candidate/joba���
#Renal #Research
Figure 1 | Patients have diverse preferences that reflect individual variation in what they consider important. Those planning for life with kidney failure want control over their futures and tend to desire autonomy in treatment decision-making. They will trade off the potential benefits of treatments against an over-riding desire to minimize disruption of daily and family life, responsibilities, and interests. The treatments that patients plan for and receive reflect complex processes involving many actors. Familial, community, societal, cultural, spiritual, clinical, and informational factors shape preferences, restrict or provide treatment options, and guide decisions. Skill, investment, and intentional practice are needed to ensure that patient preferences carry weight in decision-making.
Proud of this Kidney International paper: doi.org/10.1016/j.ki.... Nephrology involves optimal delivery of treatments that prolong life, preserve & replace organ function. The art lies in shaping this care to the person.
@rachaelmorton.bsky.social
@lucyselman.bsky.social
@flissmurtagh.bsky.social
No more fistula first, even in the @ukkidney.org vascular access guidelines
Long, helpful document: bmcnephrol.biomedcentral.com/articles/10....
#NephSky
Figure 2 (a) Kidney response to treatment. Scatter plots of individual change in eGFR at 12 months versus baseline eGFR, stratified by duration of glucocorticoid therapy, and (b) individual change in uPCR at 12 months versus baseline uPCR for the whole cohort. r values are Pearson coefficients. Alluvial plots demonstrating change in AAV classification from initial biopsy to interval biopsy (n = 19) for (c) Berden classification, and (d) ANCA Kidney Risk Score. AAV, antineutrophil cytoplasm antibody-associated vasculitis; ANCA, antineutrophil cytoplasm antibody; eGFR, estimated glomerular filtration rate; uPCR, urinary protein-to-creatinine ratio.
Vitamin R + Cyclophosohamide in ANCA vasculitis
A case series from Edinburgh suggesting this allows faster steroid withdrawal?
@kireports.bsky.social www.kireports.org/article/S246...
#NephSky #Vasculitis
🙌 @barnyhole.bsky.social @lucyselman.bsky.social
Few drugs would be licensed with a > 5 % risk of liver enzyme level elevation - why are law makers so lenient with cannabidiol?
jamanetwork.com/journals/jam...
Only reason to sequence the RASi first is that they are good antihypertensives (but note the BP effect in the combo arm of #confidence) #nephjc
But no matter the sequence, the goal should be to have someone on the four pillars in less than 6 months
SGLT2i in CKD: impact beyond kidneys
🔻 15% all-cause hospitalizations
✅ Consistent regardless of eGFR, UACR & diabetes
🏥 ~36 fewer hospitalizations per 1000 pt-years
Large absolute gains for patients & health systems
Meta-analysis in @asnpublications.bsky.social
journals.lww.com/cjasn/pages/...
9/10 I want more info:
✅Check out #NephJC summary by @sejalplakhani.bsky.social & @jeyakumarmeyyappan.bsky.social
www.nephjc.com/news/confide...
✅Visual abstract by @shelliefravel.bsky.social
www.nephjc.com/news/2025/7/...
1/10
Last #NephJC we discussed the combination therapy of empagliflozin and finerenone 💊 #TenPostNephJC
🌵From a therapeutic dessert to a flood of options in diabetic kidney disease (DKD) - what is the best timing to keep the kidneys afloat
📢 In BMJo: That’s why I wanted him to go on dialysis-a qualitative analysis of older patients’ & family members’ perspectives on kidney failure treatment rdcu.be/ewi4l
@lucyselman.bsky.social
@leilarooshenas.bsky.social
@peolcsw.bsky.social
@wolfsonpallcare.bsky.social
@flissmurtagh.bsky.social
🎨 Beautiful visual abstract by @shelliefravel.bsky.social #NephJC
www.nephjc.com/news/...
T0b: #NephJC
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
A letter with visible logos of Kidney Care UK, Kidney Research UK, PKD Charity, UK Kidney Association and The National Kidney Federation at the bottom, addressing important health policy commitments.
🖊️ Do you feel #KidneyDisease is overlooked? It’s time to act. Sign our open letter to the Prime Minister calling for a national #CKDstrategy & a better future for kidney patients 👉 www.ukkidney.org/prime-minist...
@Kidney_Research @kidneycareuk @NKF_UK @PKDCharity @UKKidney
www.kireports.org/article/S246... If all roads to lead to dialysis, the kidney failure population will experience unmet needs unseen for decades. @lucyselman.bsky.social @flissmurtagh.bsky.social @kidneycoalition.bsky.social @rcpdmeetings.bsky.social @kidneyint.bsky.social
🧠 New publication
latent TB screening in CKD
📈 TB incidence in UK dialysis patients > some high-burden countries, yet national screening guidance unclear.
We call for equitable access
👉 : doi.org/10.1093/ckj/...
#Nephrology #TB #CKD #LTBI #PublicHealth #Dialysis #HealthEquity #MigrationHealth
Figure 2
Figure 5
Huge Danish trial of nudges
Patient level (N 22,000)
+ practice level (1500 practice cluster with N 28,000 pts)
To increase RASination & Flozination
www.ahajournals.org/doi/abs/10.1... in @ahajournals.bsky.social at #ERA25
Absolutely null effect - is the baseline too high to improve upon?
Do you think there is ever a place for tolvaptan in 'diuretic resistant' right sided heart failure plus with sodium in the low 110s? Something I've been asked today.
Core Curriculum by @nephcrit.bsky.social , @hswapnil.medsky.social , Abdulghani Omar Kabli, Oleksa G. Rewa, and Edward G. Clark:
Continuous Kidney Replacement Therapies: Core Curriculum 2025
bit.ly/TeixeiraCC25 (FREE)
Foundational therapies in ESRD for heart failure
Dr Matt Graham-Brown from Leicester presents at #NephGR
www.youtube.com/watch?v=Ar11...
(Rounds from Feb, late share!)
Figure of survival curve showing no difference
There you have it: BEDMED published in @jama.com
jamanetwork.com/journals/jam...
h/t @drjmluther.bsky.social
No difference in bedtime versus morning BP meds - as expected
#NephSky #Hypertension
1/
@kidneyresearchuk.org are enabling pharmacist-led research. I applied last year www.kidneyresearchuk.org/2025/04/22/p... Supported by @kindaibrahim @rosalynnaustin @jigneshpatel @davidwheeler @ukkidney.org @arcwessex.bsky.social
Genetic mutations in the terminal complement system may lead to increased susceptibility to preeclampsia. Targeting the terminal complement pathway could be a potential therapeutic strategy.
bit.ly/KN1705-19
@silvishah.bsky.social
#ASNKidneyNews
📢 New @RenalRadar paper!
The study explores how nephrotic syndrome progresses & the link between proteinuria & kidney failure risk.
🔍 Insights will help clinicians identify higher risk patients earlier & improve clinical trial design.
Read more 👉 ow.ly/xVyz50VTPQP
Promising!
flozination in ADPKD (mostly older adults with DM or CVD) - presumably those with another valid indication - associated with slower GFR slope
journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social #CJASN
With no obvious harm signal
The ADPKD @kdigo.org guideline episode of @freelyfiltered.bsky.social
www.nephjc.com/freelyfilter...
Joel, Nayan, AC, with Sophia Ambruso coining a new word for posting here (bleat!)
And Charles Edelstein dropping lot of wisdom + @rheaultm.bsky.social with a cameo
#NephSky
💡New SPOTLIGHT ✨
As part of our 75th celebrations, we're featuring the AKI SIG — a powerhouse of collaboration.
From mapping UK AKI services to developing the world’s first AKI Master Patient Index, the group is transforming #AKICare👏
Explore more about the SIG's work: www.ukkidney.org/75-...